Transfusion Medicine Reviews
Volume 17, Issue 1 , Pages 45-56 , January 2003

Understanding platelet function through signal transduction

  • Alan H. Lazarus

      Affiliations

    • Department of Laboratory Medicine and Pathobiology, St. Michael's Hospital Toronto, Ontario, Canada
    • The Canadian Blood Services, Toronto, Ontario, Canada
    • The Toronto Platelet Immunobiology Group, Toronto, Ontario, Canada
    • Corresponding Author InformationAddress reprint requests to Alan H. Lazarus, PhD, Transfusion Medicine Research, St. Michael's Hospital, 30 Bond St., Toronto, Ontario, Canada M5B 1W8.
    • ,
  • Seng Song

      Affiliations

    • Department of Laboratory Medicine and Pathobiology, St. Michael's Hospital Toronto, Ontario, Canada
    • The Canadian Blood Services, Toronto, Ontario, Canada
    • The Toronto Platelet Immunobiology Group, Toronto, Ontario, Canada
    • ,
  • Andrew R. Crow

      Affiliations

    • Department of Laboratory Medicine and Pathobiology, St. Michael's Hospital Toronto, Ontario, Canada
    • The Canadian Blood Services, Toronto, Ontario, Canada
    • The Toronto Platelet Immunobiology Group, Toronto, Ontario, Canada

References 

  1. Blake RA, Walker TR, Watson SP. Activation of human platelets by peroxovanadate is associated with tyrosine phosphorylation of phospholipase C gamma and formation of inositol phosphates. Biochem J. 1993;290:471–475
  2. McNicol A, Robertson C, Gerrard JM. Vanadate activates platelets by enhancing arachidonic acid release. Blood. 1993;81:2329–2338
  3. Pumiglia KM, Lau LF, Huang CK, et al. Activation of signal transduction in platelets by the tyrosine phosphatase inhibitor pervandate (vanadyl hydroperoxide). Biochem J. 1992;286:441–449
  4. Pasquet JM, Quek L, Pasquet S, et al. Evidence of a role for SHP-1 in platelet activation by the collagen receptor glycoprotein VI. J Biol Chem. 2000;275:28526–28531
  5. Judd BA, Koretzky GA. The role of the adapter molecule SLP-76 in platelet function. Oncogene. 2001;20:6291–6299
  6. Cho MJ, Pestina TI, Steward SA, et al. The roles of LAT in platelet signaling induced by collagen, TxA2, or ADP. Biochem Biophys Res Commun. 2002;292:916–921
  7. Saci A, Liu WQ, Vidal M, et al. Differential effect of the inhibition of Grb2-SH3 interactions in platelet activation induced by thrombin and by Fc receptor engagement. Biochem J. 2002;363:717–725
  8. Schwartz UR, Walter W, Eigenthaler M. Taming platelets with cyclic nucleotides. Biochem Pharmacol. 2001;62:1153–1161
  9. Barry FA, Gibbins JM. Protein kinase B is regulated in platelets by the collagen receptor glycoprotein VI. J Biol Chem. 2002;277:12874–12878
  10. Ezumi Y, Uchiyama T, Takayama H. Thrombopoietin potentiates the protein-kinase-C-mediated activation of mitogen-activated protein kinase/ERK kinases and extracellular signal-regulated kinases in human platelets. Eur J Biochem. 1998;258:976–985
  11. Miyakawa Y, Oda A, Druker BJ, et al. Thrombopoietin induces tyrosine phosphorylation of Stat3 and Stat5 in human blood platelets. Blood. 1996;87:439–446
  12. Song S, Freedman J, Mody M, et al. p38 MAPK is activated but not necessary in porcine von Willebrand factor-dependent platelet activation. Br J Haematol. 1999;107:532–538
  13. Song S, Freedman J, Mody M, et al. Porcine von Willebrand factor and thrombin induce the activation of c- Jun amino-terminal kinase (JNK/SAPK) whereas only thrombin induces activation of extracellular signal-related kinase 2 (ERK2) in human platelets. Br J Haematol. 2000;109:851–856
  14. Available at Accessed October 1, 2001 Whitmarsh AJ, Davis RJ. Signal transduction by MAP kinases: Regulation by phosphorylation-dependent switches. Sci STKE 1999:pel. 1999.
  15. Mody M, Lazarus AH, Semple JW, et al. Preanalytical requirements for flow cytometric evaluation of platelet activation: Choice of anticoagulant. Transfus Med. 1999;9:147–154
  16. Clutton P, Folts JD, Freedman JE. Pharmacological control of platelet function. Pharmacol Res. 2001;44:255–264
  17. Torti M, Bertoni A, Canobbio I, et al. Rap 1B and Rap2B translocation to the cytoskeleton by von Willebrand factor involves Fcgammall receptor-mediated protein tyrosine phosphorylation. J Biol Chem. 1999;274:13690–13697
  18. Wolthuis RM, Franke B, van Triest M, et al. Activation of the small GTPase Ral in platelets. Mol Cell Biol. 1998;18:2486–2491
  19. Suzuki-Inoue K, Yatomi Y, Asazuma N, et al. Rac, a small guanosine triphosphate-binding protein, and p21-activated kinase are activated during platelet spreading on collagencoated surfaces: Roles of integrin alpha(2)beta(1). Blood. 2001;98:3708–3716
  20. Fox JE. Cytoskeletal proteins and platelet signaling. Thromb Haemost. 2001;86:198–213
  21. Payrastre B, Missy K, Trumel C, et al. The integrin alpha IIb/beta 3 in human platelet signal transduction. Biochem Pharmacol. 2000;60:1069–1074
  22. Macfarlane SR, Seatter MJ, Kanke T, et al. Proteinase-activated receptors. Pharmacol Rev. 2001;53:245–282
  23. Quek LS, Pasquet JM, Hers I, et al. Fyn and Lyn phosphorylate the Fc receptor gamma chain downstream of glycoprotein VI in murine platelets, and Lyn regulates a novel feedback pathway. Blood. 2000;96:4246–4253
  24. Bodin S, Giuriato S, Ragab J, et al. Production of phosphatidylinositol 3,4,5-trisphosphate and phosphatidic acid in platelet rafts: Evidence for a critical role of cholesterol- enriched domains in human platelet activation. Biochemistry. 2001;40:15290–15299
  25. Asazuma N, Wilde JI, Berlanga O, et al. Interaction of linker for activation of T cells with multiple adapter proteins in platelets activated by the glycoprotein VI-selective ligand, convulxin. J Biol Chem. 2000;275:33427–33434
  26. Tulasne D, Bori T, Watson SP. Regulation of RAS in human platelets. Eur J Biochem. 2002;269:1511–1517
  27. Asazuma N, Ozaki Y, Satoh K, et al. Glycoprotein Ib-von Willebrand factor interactions activate tyrosine kinases in human platelets. Blood. 1997;90:4789–4798
  28. Falati S, Edmead CE, Poole AW. Glycoprotein Ib-V-IX, a receptor for von Willebrand factor, couples physically and functionally to the Fc receptor gamma-chain, Fyn, and Lyn to activate human platelets. Blood. 1999;94:1648–1656
  29. Canobbio I, Bertoni A, Lova P, et al. Platelet activation by von Willebrand factor requires coordinated signaling through thromboxane A2 and Fc gamma IIA receptor. J Biol Chem. 2001;276:26022–26029
  30. Krol MH, Hellums JD, Guo Z, et al. Protein kinase C is activated in platelets subjected to pathological shear stress. J Biol Chem. 1993;268:3520–3524
  31. Wu Y, Suzuki-Inoue K, Satoh K, et al. Role of Fc receptor gamma-chain in platelet glycoprotein Ib-mediated signaling. Blood. 2001;97:3836–3845
  32. Francesconi MA, Deana R, Girolami A, et al. Platelet aggregation induced by plasma from type IIB von Willebrand's disease patients is associated with an increase in cytosolic Ca2+ concentration. Thromb Haemost. 1993;70:697–701
  33. Francesconi M, Casonato A, Pontara E, et al. Type IIB von Willebrand factor induces phospholipase A2 activation and cytosolic Ca2+ increase in platelets. Biochem Biophys Res Commun. 1995;214:102–109
  34. Kroll MH, Harris TS, Moake JL, et al. von Willebrand factor binding to platelet GpIb initiates signals for platelet activation. J Clin Invest. 1991;88:1568–1573
  35. Kermode JC, Zheng Q, Milner EP. Marked temperature dependence of the platelet calcium signal induced by human von Willebrand factor. Blood. 1999;94:199–207
  36. Pareti FI, Mazzucato M, Bottini E, et al. Interaction of porcine von Willebrand factor with the platelet glycoproteins Ib and IIb/IIIa complex. Br J Haematol. 1992;82:81–86
  37. Song, S, Mody, M, Freedman, J, et al. Von Willebrand factor (vWF)-dependent human platelet activation: Porcine vWF utilizes different transmembrane signaling pathways than does thrombin to activate platelets, but both require protein phosphatase function. J Thromb Haem (in press)
  38. Anderson CL, Chacko GW, Osborne JM, et al. The Fc receptor for immunoglobulin G (Fc gamma RII) on human platelets. Semin Thromb Hemost. 1995;21:1–9
  39. Chacko GW, Duchemin AM, Coggeshall KM, et al. Clustering of the platelet Fc gamma receptor induces noncovalent association with the tyrosine kinase p72syk. J Biol Chem. 1994;269:32435–32440
  40. Huang MM, Indik Z, Brass LF, et al. Activation of Fc gamma RII induces tyrosine phosphorylation of multiple proteins including Fc gamma RII. J Biol Chem. 1992;267:5467–5473
  41. Blake RA, Asselin J, Walker T, et al. Fc gamma receptor II stimulated formation of inositol phosphates in human platelets is blocked by tyrosine kinase inhibitors and associated with tyrosine phosphorylation of the receptor. FEBS Lett. 1994;342:15–18
  42. Daniel JL, Dangelmaier C, Smith JB. Evidence for a role for tyrosine phosphorylation of phospholipase C gamma 2 in collagen-induced platelet cytosolic calcium mobilization. Biochem J. 1994;302:617–622
  43. Horsewood P, Hayward CP, Warkentin TE, et al. Investigation of the mechanisms of monoclonal antibody-induced platelet activation. Blood. 1991;78:1019–1026
  44. Rubinstein E, Urso I, Boucheix C, et al. Platelet activation by cross-linking HLA class I molecules and Fc receptor. Blood. 1992;79:2901–2908
  45. Warkentin TE, Chong BH, Greinacher A. Heparin-induced thrombocytopenia: Towards consensus. Thromb Haemost. 1998;79:1–7
  46. Horne MK, Alkins BR. Platelet binding of IgG from patients with heparin-induced thrombocytopenia. J Lab Clin Med. 1996;127:435–442
  47. Christie DJ, Leja DN, Carlson DL, et al. Characterization of platelet activation induced by HLA antibodies associated with alloimmune thrombocypenia. J Lab Clin Med. 1993;121:437–443
  48. Dettke M, Dreer M, Hocker P, et al. Human platelet antigen-la antibodies induce the release of the chemokine RANTES from human platelets. Vox Sang. 2001;81:199–203
  49. Brandt JT, Julius CJ, Osborne JM, et al. The mechanism of platelet aggregation induced by HLA-related antibodies. Thromb Haemost. 1996;76:774–779
  50. Kretschmer V, Huss B, Feller K, et al. Influence of HPA-1a and HLA antibodies on primary hemostasis. Semin Thromb Hemost. 1995;21:96–102
  51. Terness P, Berteli A, Susal C, et al. Regulation of antibody response by an IgG-anti-Ig autoantibody occurring during alloimmunization II. Selective inactivation of antigen receptor-occupied B cells. Transplantation. 1992;54:92–96
  52. Terness P, Susal C, Baur C, et al. A B cell-suppressive IgG-antiimmunoglobulin antibody induced by alloimmunization. Transplantation. 1990;50:502–505
  53. Terness P, Opelz G. Regulation of antibody response by an IgG-anti-Ig autoantibody occurring during alloimmunization. I. A few IgG molecules inactivate one B cell. Transplantation. 1992;54:88–91
  54. Atlas E, Freedman J, Blanchette V, et al. Downregulation of the anti-HLA alloimmune response by variable region-reactive (anti-idiotypic) antibodies in leukemic patients transfused with platelet concentrates. Blood. 1993;81:538–542
  55. Crow AR, Freedman J, Hannach B, et al. Monoclonal antibody-mediated inhibition of the human HLA alloimmune response to platelet transfusion is antigen specific and independent of Fcgamma receptor-mediated immune suppression. Br J Haematol. 2000;110:481–487
  56. Seghatchian J, Krailadsiri P. The platelet storage lesion. Transfus Med Rev. 1997;11:130–144
  57. Bode AP. Platelet activation may explain the storage lesion in platelet concentrates. Blood Cells. 1990;16:109–125
  58. Levy-Toledano S, Gallet C, Nadal F, et al. Phosphorylation and dephosphorylation mechanisms in platelet function: A tightly regulated balance. Thromb Haemost. 1997;78:226–233
  59. Estebanell E, Diaz-Ricart M, Escolar G, et al. Alterations in cytoskeletal organization and tyrosine phosphorylation in platelet concentrates prepared by the buffy coat method. Transfusion. 2000;40:535–542
  60. Hernandez-Hernandez A, Sanchez-Bernal C, Rodriguez MC, et al. Loss of phosphotyrosine phosphatase activity and changes in the tyrosine phosphorylation state of proteins after storage of sheep platelets in plasma or Seto solution at 4 degrees C. Vox Sang. 2001;81:241–247
  61. Cho MJ, Pestina TI, Steward SA, et al. Role of the Src family kinase Lyn in TxA2 production, adenosine diphosphate secretion, Akt phosphorylation, and irreversible aggregation in platelets stimulated with gamma-thrombin. Blood. 2002;99:2442–2447
  62. Jantzen HM, Milstone DS, Gousset L, et al. Impaired activation of murine platelets lacking G alpha(i2). J Clin Invest. 2001;108:477–483
  63. Tibbles HE, Vassilev A, Wendorf H, et al. Role of a JAK3-dependent biochemical signaling pathway in platelet activation and aggregation. J Biol Chem. 2001;276:17815–17822
  64. Quek LS, Pasquet JM, Hers I, et al. Fyn and Lyn phosphorylate the Fc receptor gamma chain downstream of glycoprotein VI in murine platelets, and Lyn regulates a novel feedback pathway. Blood. 2000;96:4246–4253
  65. Konishi H, Katoh Y, Takaya N, et al. Platelets activated by collagen through immunoreceptor tyrosine-based activation motif play pivotal role in initiation and generation of neointimal hyperplasia after vascular injury. Circulation. 2002;105:912–916
  66. Nieswandt B, Brakebusch C, Bergmeier W, et al. Glycoprotein VI but not alpha2betal integrin in essential for platelet interaction with collagen. Embo J. 2001;20:2120–2130
  67. Jones KL, Hughan SC, Dopheide SM, et al. Platelet endothelial cell adhesion molecule-1 is a negative regulator of platelet-collagen interactions. Blood. 2001;98:1456–1463
  68. Hirsch E, Bosco O, Tropel P, et al. Resistance to thromboembolism in PI3Kgamma-deficient mice. Faseb J. 2001;15:2019–2021
  69. Offermanns S, Toombs CF, Hu YH, et al. Defective platelet activation in G alpha(q)-deficient mice. Nature. 1997;389:183–186
  70. Azam M, Andrabi SS, Sahr KE, et al. Disruption of the mouse mu-calpain gene reveals an essential role in platelet function. Mol Cell Biol. 2001;21:2213–2220
  71. Smyth SS, Tsakiris DA, Scudder LE, et al. Structure and function of murine alphaIIbbeta3 (GPIIb/IIIa): Studies using monoclonal antibodies and beta3-null mice. Thromb Haemost. 2000;84:1103–1108
  72. Helgason CD, Damen JE, Rosten P, et al. Targeted disruption of SHIP leads to hemopoietic perturbations, lung pathology, and a shortened life span. Genes Dev. 1998;12:1610–1620
  73. Soriano P, Montgomery C, Geske R, et al. Targeted disruption of the c-src proto-oncogene leads to osteopetrosis in mice. Cell. 1991;64:693–702
  74. Ganiatsas S, Kwee L, Fujiwara Y, et al. SEK1 deficiency reveals mitogen-activated protein kinase cascade crossregulation and leads to abnormal hepatogenesis. Proc Natl Acad Sci U S A. 1998;95:6881–6886
  75. Yang DD, Conze D, Whitmarsh AJ, et al. Differentiation of CD4+ T cells to Th1 cells requires MAP kinase JNK2. Immunity. 1998;9:575–585
  76. Dong C, Yang DD, Wysk M, et al. Defective T cell differentiation in the absence of Jnk1. Science. 1998;282:2092–2095
  77. Turner M, Mee PJ, Costello PS, et al. Perinatal lethality and blocked B-cell development in mice lacking the tyrosine kinase Syk. Nature. 1995;378:298–302
  78. Naramura M, Kole HK, Hu RJ, et al. Altered thymic positive selection and intracellular signals in Cbl-deficient mice. Proc Natl Acad Sci U S A. 1998;95:15547–15552
  79. Bachmaier K, Krawczyk C, Kozieradzki I, et al. Negative regulation of lymphocyte activation and autoimmunity by the molecular adaptor Cbl-b. Nature. 2000;403:211–216
  80. Khan WN, Sideras P, Rosen FS, et al. The role of Bruton's tyrosine kinase in B-cell development and function in mice and man. Ann N Y Acad Sci. 1995;764:27–38
  81. Meng F, Lowell CA. Lipopolysaccharide (LPS)-induced macrophage activation and signal transduction in the absence of Src-family kinases Hck, Fgr, and Lyn. J Exp Med. 1997;185:1661–1670
  82. Stein PL, Vogel H, Soriano P. Combined deficiencies of Src, Fyn, and Yes tyrosine kinases in mutant mice. Genes Dev. 1994;8:1999–2007

PII: S0887-7963(03)80004-4

doi: 10.1053/tmrv.2003.50002

Transfusion Medicine Reviews
Volume 17, Issue 1 , Pages 45-56 , January 2003

Article Tools